Key Takeaways
- Soft quarter, margin hit: Domestic volumes declined 1.2% and EBITDA fell 29% YoY as unprecedented input cost inflation and a high base from COVID-contextual products compressed gross margins by 230 bps.
- Investment spend stayed on: A&P spend rose 400 bps and distribution investments continued despite the demand softness, a deliberate choice to support brands for the long term and capture a rural recovery.
- Channel shift accelerated: Modern Trade and e-commerce combined contribution jumped from 11.3% to 16.5% of domestic revenues, while wholesale and rural channels lagged.
- International business provided a buffer: International revenues grew 17%, led by MENA and CIS markets, cushioning the domestic slowdown.
- What to watch next quarter: Whether the buoyancy seen in wholesale markets in the last 10-15 days sustains for another 30-40 days, and if gross margins indeed stabilise as input cost pressure eases.
Demand & Volume Trends
- Domestic softness: Muted demand sentiment persisted due to high inflation, rural slowdown, and liquidity pressure. Domestic volume degrowth of 1.2% was optically muted, but management pointed to an 8% three-year CAGR given the headwinds of the last 2-3 years.
- Rural-urban divergence: A significant gap opened up, with wholesale behaving like rural and declining, while Modern Trade, general trade retail, and e-commerce grew at roughly twice the rural rate.
- Category-specific pain: The oil portfolio saw down-trading, with consumers using oils less than earlier. Navratna Extra Thanda oil pulled down the portfolio post-COVID as people avoided cold-inducing products, though base Navratna Oil still grew. Kesh King declined 10% YoY, pressured by its sizable rural contribution.
- Early green shoots: Management noted buoyancy in wholesale markets in the last 10-15 days post-holiday season, particularly for winter products and across the board, and said if the trend continues another 30-40 days, it is very optimistic on good numbers.
Mohan Goenka: "We are very confident that the markets should improve today or tomorrow. In fact, let me also share that we are happy to see the numbers coming in the last 10, 15 days, post all the holiday season. So there is some buoyancy coming in, in the wholesale markets, particularly for the winter products and it is across the board."
Margins & Cost Structure
- Gross margin compression: Gross margins contracted 230 bps, driven by unprecedented inflationary pressure and an unfavourable portfolio mix comparison against last year's extraordinary high sales of the pain management range.
- A&P spend stepped up: Advertising and promotion spend rose 400 bps because the company chose not to cut advertising despite input cost pressure, viewing it as essential raw material to grow the market when a recovery is expected.
- EBITDA decline drivers: The 29% YoY EBITDA decline reflected inclusion of new subsidiary costs (Helios), upfront marketing investments, and strategic outlay on distribution expansion in Rural and Modern Trade channels, all against muted sales growth that prevented operating leverage.
- Input cost relief ahead: Management expressed confidence that input cost pressure has eased off quite a bit and that no margin pressures are expected in Q3. With moderation in input cost inflation, not much pressure on gross margins is expected in H2 FY23.
- Full-year margin framework: For the core business excluding Helios, EBITDA margin is expected around pre-COVID levels of ~27%. Helios is expected to deplete reported margins by at most 0.2%-0.3% in H2. Ad spends are pegged at around 16.5-17% in that 27% margin scenario.
Mohan Goenka: "We are committed to invest behind our brands and also to invest behind the distribution channels. Also, we see very healthy growth coming in from the Healthcare channels. So we have a lot of investments to do going forward. And so margins should be in the pre-COVID levels around 27%. If natural margin expansion happens, it happens. Otherwise, you should expect around 27% margins."
Brand & Portfolio Health
- Pain management and healthcare corrections: Declines were broadly in line with expectations due to a high base and decline in consumption of COVID-contextual products. Versus FY19-20, both OTC and medical businesses were performing well; the base effect was the challenging factor this year.
- Kesh King: The 10% YoY decline was attributed to a sluggish overall market with sizable rural contribution seeing pressures. Channels where the company invested, Modern Trade and e-commerce, showed healthy growth on Kesh King, indicating healthy offtake. The effect was described as temporary, linked to inflationary pressures largely due to rural.
- Navratna: Degrowth occurred despite a non-high sales base, with Extra Thanda oil pulling down the portfolio post-COVID. Management is hopeful of positive growth in the next season with a new campaign as the COVID effect fades.
- BoroPlus: Q2 growth was primarily loading, but good secondaries were also coming in as winter set in well across India. The company expects double-digit growth for the full year and is being aggressive with a new campaign featuring Akshay Kumar.
- New product development: NPD contribution is expected to ramp to ~3% of sales going forward, with a significant pipeline in Zandu and the existing range. The company has decided to launch digital-first brands on the existing range and the Zandu D2C platform, priced at a premium and with a clear intent not to dilute margins for e-commerce and Modern Trade channels.
Mohan Goenka: "Our aspirations may not be so high, Abneesh. It has come as a range. But we don't want to dilute our margins. That is very, very clear."
Channel & Distribution
- Channel mix transformation: Modern Trade and e-commerce combined contribution rose from 11.3% to 16.5% of domestic revenues, reflecting strong growth in these channels even as wholesale declined.
- Rural distribution strategy: The Khoj project consolidated its footprint in the first two quarters rather than expanding, given the demand environment. Value per town/village did not drop, and van cost savings were plowed back into the business. The target remains 50,000 villages by year-end, with expansion resuming from December onwards, and an additional ~10,000 villages per year over the next two years, provided cost-of-sales benchmarks are met.
- Healthcare channel investment: Increased manpower coverage in retail and up-country markets is expected to show results in the next few months, with better overall performance anticipated from the next quarter onwards versus last year.
International Business
- Topline performance: International business grew 17% on good performance across markets. MENA, Russia, and CIS markets performed better than SAARC and Southeast Asia.
- CIS resilience: The CIS region continued to grow despite disturbances, a result of own infrastructure built in previous years.
- SAARC headwinds: Sri Lanka volumes dipped after sharp currency depreciation in March but were recovering from August. Bangladesh faced dollar availability issues, leaving fundamental business fine but new initiatives pulling down due to inability to invest. Nepal faced macroeconomic issues. SAARC markets were nonetheless showing signs of recovery.
- Manufacturing localisation: Approximately 70% of GCC sales are now manufactured outside India, and by end of FY23, the company expects to reach maximum localisation objectives.
- Near-term outlook: Q3 international growth is expected at ~12-14%, with the Asian side turning around and initiatives on brand, manufacturing, and infrastructure continuing to yield results.
Vivek Dhir: "Macroeconomic is not in our hands, but our actions to overcome those issues are in our hands. So we are working around that area so that these markets also continue to perform for this."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Core EBITDA margin | ~27% (pre-COVID level), excluding Helios | FY23 full year |
| Helios margin impact | Max 0.2%-0.3% depletion on reported margins | H2 FY23 |
| Gross margin pressure | Not much pressure expected as input cost inflation moderates | H2 FY23 |
| Input cost pressure | No margin pressures expected | Q3 FY23 |
| BoroPlus growth | Double-digit growth | FY23 full year |
| International growth | ~12-14% growth | Q3 FY23 |
| GCC manufacturing localisation | Reach maximum localisation objectives | By end FY23 |
| Rural distribution footprint | Reach 50,000 villages; then add ~10,000 villages/year | By year-end; next 2 years |
| NPD contribution | Ramp to ~3% of sales | Going forward |
| MAT credit utilisation | Tax rate below 10% for FY23, ~10% for next year | FY23; FY24 |
| Kesh King amortisation | Run rate of ₹45-50 crore/quarter to continue | Next few quarters |
| Dermicool, Creme 21 amortisation | ~₹23.5 crore/quarter to continue | For some time |
| Healthcare performance | Better overall performance vs last year | From next quarter onwards |
Key Metrics
| Metric | Q2 FY23 |
|---|---|
| Net sales | ₹807 cr, +4% YoY |
| Revenue | ₹814 cr, +3% YoY |
| Domestic business growth | +1.2% YoY, volume degrowth of 1.2% |
| Domestic business 3-year CAGR | 8% |
| Core domestic business growth | +5% YoY, excluding pain management, healthcare range, and Helios Lifestyle |
| Gross margin | 66.6%, contracted 230 bps YoY |
| A&P spend | increased 400 bps YoY |
| EBITDA | ₹195 cr, declined 29% YoY |
| Profit before tax | ₹186 cr, declined 18% YoY |
| Profit after tax | ₹180 cr, declined 3% YoY |
| H1 FY23 EBITDA margin | 23.2%, lower by 760 bps YoY |
| Full-year EBITDA margin guidance (core business) | ~27%, pre-COVID levels |
| International business growth | +17% YoY |
| Modern Trade growth | +28% YoY |
| E-commerce growth | +56% YoY |
| Modern Trade + E-commerce share of domestic revenue | 16.5%, up from 11.3% in Q2 FY22 |
| BoroPlus range growth | +17% YoY |
| Kesh King range growth | -10% YoY, 3-year CAGR of 14% |
| Pain Management range growth | -13% YoY |
| Healthcare range growth | -16% YoY |
| Helios Lifestyle (The Man Company) contribution to net sales | 3.5% |
| Zanducare online run rate | ~₹2 cr per month |
| NPD contribution to sales | ~1–1.5%, expected to ramp to ~3% |
| Rural distribution footprint | 42,000 villages, target 50,000 by year-end |
| Effective tax rate guidance (FY23) | below 10%, due to MAT credit utilization |